Insider · CIK 0001606241
Stephen R Brady
Files at TPST (Tempest Therapeutics, Inc.). First filing -, latest -.
In brief
Stephen R Brady files SEC Form 4 as CEO, president and director at TPST (Tempest Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Stephen R Brady has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2025 | TPST Tempest Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +550,000 | $0.00 | $0 | 550,000 | Jan 6, 2025 |
| Jan 3, 2024 | TPST Tempest Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Jan 5, 2024 |
| Oct 11, 2023 | TPST Tempest Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +725,000 | $0.00 | $0 | 725,000 | Oct 13, 2023 |
Questions about Stephen R Brady
Answered from the filings on this page, as of the latest one.
Is Stephen R Brady buying or selling?
Stephen R Brady has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Stephen R Brady's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Stephen R Brady has 0.
Where does Stephen R Brady file Form 4?
Stephen R Brady has filed Form 4 at TPST (Tempest Therapeutics, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.